Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas
2026年 6月 16日
Read MoreZai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer
2026年 6月 8日
Read MoreZai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates
2026年 5月 7日
Read MoreZai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026
2026年 4月 22日
Read MoreZai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases
2026年 4月 18日
Read MoreZai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas
2026年 4月 17日
Read More